Short answer: brand-name GLP-1 medications such as Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved. Compounded semaglutide and tirzepatide are prepared by a pharmacy for an individual patient and are not FDA-approved — the FDA does not review them for safety, effectiveness, or quality before they are dispensed.
This article is educational and is not medical advice. Whether any treatment is appropriate for you is decided by a licensed clinician after reviewing your health history.
What is a compounded medication?
Compounding is when a licensed pharmacist combines, mixes, or alters ingredients to create a medication tailored to an individual patient's needs. The FDA explains that compounding can serve an important patient need, for example when a patient cannot use an approved drug — but compounded drugs are not FDA-approved. See FDA: Compounding and the FDA — Questions and Answers.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is not the same as any branded semaglutide product, and compounded tirzepatide is not the same as Zepbound or Mounjaro. The brand-name products went through FDA review of their safety, effectiveness, and manufacturing quality; compounded versions do not.
When can a GLP-1 be compounded?
The FDA declared the national tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Since then, compounded versions may generally be prepared only for an individual patient when a licensed clinician documents a specific clinical reason the approved product is unsuitable — not for cost or convenience. See FDA: compounding laws and policies and Can compounded semaglutide still be prescribed?.
What safety issues has the FDA raised?
The FDA has published several concerns about compounded GLP-1s (FDA's concerns with unapproved GLP-1 drugs):
- Adverse-event reports. As of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The FDA notes it is not always possible to confirm that a report was caused by the product.
- Dosing errors. The FDA has received reports — some involving hospitalization — of patients measuring and self-injecting incorrect doses of compounded injectable semaglutide. See FDA dosing-error alert.
- Salt forms. Semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drugs, and the FDA says salt forms should not be used to compound semaglutide.
How do I lower these risks?
- Use a service where a licensed clinician reviews your health history before any prescription.
- Make sure the medication comes from a state-licensed pharmacy, and check its license with your state board of pharmacy.
- Follow syringe-measurement instructions exactly and never estimate a dose volume.
- Ask questions before your first dose, and report side effects to your clinician and to FDA MedWatch.
How ElliotMeds handles this
Every request at ElliotMeds is reviewed by a licensed U.S. clinician, and approved treatments are filled by a licensed U.S. compounding pharmacy named in our FAQ and Terms. We state on every treatment page that compounded medications are not FDA-approved.
Sources
Every program includes a clinician chart review. When prescribed, treatments are filled by a licensed U.S. pharmacy.
Important note
Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a treatment is appropriate based on the information provided.